Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Prednisone for Initial Treatment of Chronic GVHD
NCT01066598Phase 2Terminated
- Sponsor
- University Health Network
- Start
- May 2010
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by University Health Network. Primary endpoint: Discontinuation of immunosuppressive therapy with resolution of reversible manifestations at 12 months. Started May 2010; status: terminated.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01066598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01066598.